Modify Waiting Time for Candidates Affected by Race-Inclusive Estimated Glomerular Filtration Rate (eGFR) Calculations
On Dec. 5, 2022, the OPTN Board of Directors unanimously approved the proposal Modify Waiting Time for Candidates Affected by Race-Inclusive eGFR Calculations. The policy took effect Jan. 5, 2023. Learn more.
At a glance
Current policy
In June of 2022, the Board of Directors approved Establish OPTN Requirement for Race-Neutral eGFR Calculations, which prohibits the use of race-inclusive calculations. A race-inclusive calculation can overestimate a Black candidates’ eGFR value and result in a delayed start of waiting time accrual to receive a kidney transplant. Current OPTN policy does not provide a pathway for registered candidates who have been impacted by a race-inclusive eGFR calculation to regain waiting time they could have received if a race-neutral calculation was used to estimate their GFRs.
Supporting media
Presentation
Proposed changes
- Provide transplant programs a 365-day timeframe to assess their waiting lists, gather required documentation, and submit eGFR waiting time modifications for the affected Black candidates on their waiting lists
- Transplant program participation is encouraged, but not mandatory
Anticipated impact
- What it's expected to do
- Waiting time will be restored to registered Black kidney candidates whose waiting time was affected by race-inclusive eGFR calculations that meet documentation and timeframe criteria
- Increase equity in access to transplantation by providing programs the opportunity to request eGFR waiting time modifications for affected registered candidates
- What it won't do
- Mandate transplant program participation
Terms to know
- Estimated glomerular filtration rate (eGFR): A tool used to measure how well a patient’s kidneys are functioning
- Race-neutral eGFR calculation: A tool that calculates eGFR without the use of a race variable
Click here to search the OPTN glossary
Comments
ERROR | 01/07/2026
Could not retrieve comments for this proposal.